Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Monodisperse Polysarcosine-based Highly-loaded Antibody-Drug Conjugates

17 December 2018, Version 2
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We report the synthesis of monodisperse (i.e. discrete) polysarcosine compounds and their use as a hydrophobicity masking entity for the construction of highly-loaded homogeneous β- glucuronidase-responsive antibody-drug conjugates (ADCs). The highly hydrophilic drug-linker platform described herein improves drug-loading, physicochemical properties, pharmacokinetics and in vivo antitumor efficacy of the resulting conjugates.

Keywords

Antibody-drug conjugates
ADC
Bioconjugation
Antibody
Polysarcosine
Cancer
Drug Delivery

Supplementary materials

Title
Description
Actions
Title
TOC-figure
Description
Actions
Title
ESI ChemRxiv V2
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Now Published

Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates [opens in a new tab]
Warren Viricel, Guy Fournet, Sabine Beaumel, Emeline Perrial, Sébastien Papot, Charles Dumontet, Benoît Joseph journal article
Chemical Science , Volume 10, Issue 14
Online publication date: 2019

Version History

Dec 17, 2018 Version 2

Metrics

4,791
1,004
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.7388162.v2
D O I: 10.26434/chemrxiv.7388162.v2 [opens in a new tab]

Funding

Mablink Bioscience SA
Banque Publique d'Investissement (BPI France)
Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA)

Author’s competing interest statement

Some authors are co-inventors on a PCT patent application related to this work and are shareholders of Mablink Bioscience SA.

Share